• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels

    7/22/25 4:05:00 PM ET
    $PACB
    $QGEN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PACB alert in real time by email
    • Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing
    • Supports NGS platforms such as PacBio for applications including structural variants, HLA typing and repeat expansions
    • QIAGEN supporting fully integrated workflow from best-in-class sample preparation through to powerful bioinformatics for analysis and interpretation

    QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enrichment solutions designed to unlock long-read sequencing of genomically complex regions.

    This new offering strengthens QIAGEN's position as a provider of differentiated solutions for use on any next-generation sequencing (NGS) platforms spanning both short- and long-read technologies.

    The new QIAGEN panels are optimized for use with native long-read platforms, including from PacBio (NASDAQ:PACB), and designed to enable researchers to capture a broader spectrum of genomic variation. Applications include HLA typing, repeat expansion analysis, and the detection of structural variants – areas where short-read sequencing have been shown to have challenges.

    "This launch is a major milestone in our genomics strategy and reflects our long-term commitment to enabling cutting-edge science," said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. "We are making investments into our portfolio supporting NGS applications to expand the boundaries of what's possible in areas like immune profiling, complex disease genetics and cancer biology. Our goal is to empower researchers with deeper genomic insights, but also to accelerate the translation of discoveries into future clinical applications."

    "We are excited to expand our targeted sequencing offerings in partnership with QIAGEN. These new panels launch at a time when we're seeing enthusiastic adoption of our benchtop sequencer, Vega, which leverages the power of HiFi sequencing. With its long reads, exceptional accuracy, and ability to resolve complex genomic regions, HiFi is unlocking new possibilities in targeted sequencing—especially in clinical and translational research applications," said David Miller, Vice President, Global Marketing, at PacBio.

    Built on QIAGEN's proven hybrid-capture chemistry, the QIAseq xHYB Long Read Panels deliver:

    • High target completeness and uniformity
    • Flexible panel formats – including fixed panels for hereditary cancers and HLA typing, as well as customizable panels
    • Compatibility with high-molecular-weight DNA extraction kits
    • Seamless integration with QIAGEN Digital Insights bioinformatics for streamlined data interpretation

    The launch comes as long-read sequencing gains momentum in areas such as translational and clinical research. Unlike synthetic long-read or short-read technologies, native long-read sequencing provides greater insight into complex genomic regions designed to improve accuracy in haplotype phasing, repeat detection and variant resolution.

    QIAGEN's expanded portfolio now allows researchers to choose between short- and long-read sequencing – or combine them – depending on their sample type and research objectives.

    QIAGEN's end-to-end NGS solutions empower genomic discovery across research and clinical settings. The portfolio integrates robust extraction kits and instruments for diverse and challenging sample types with dedicated target enrichment panels and streamlined library preparation and quality control automation. These solutions support whole genome, transcriptome, exome, targeted and RNA sequencing, and are compatible with major sequencing platforms. Following sequencing, advanced bioinformatics tools translate complex NGS data into actionable biological insights, enabling applications in academic research, biopharma and oncology.

    To learn more about QIAseq xHYB Long Read Panels, visit www.qiagen.com/qiaseq-long-read-seq.

    About QIAGEN

    QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.

    Forward-Looking Statement

    Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the "Risk Factors" contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.

    Source: QIAGEN N.V.

    Category: PCR & Genomics

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250722620965/en/

    Contact QIAGEN

    Investor Relations

    e-mail: [email protected]

    Public Relations

    e-mail: [email protected]

    Get the next $PACB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PACB
    $QGEN

    CompanyDatePrice TargetRatingAnalyst
    Qiagen N.V.
    $QGEN
    6/24/2025$55.00Overweight
    Barclays
    Qiagen N.V.
    $QGEN
    4/4/2025Buy → Neutral
    Redburn Atlantic
    Qiagen N.V.
    $QGEN
    2/19/2025$52.00 → $42.00Outperform → Neutral
    Robert W. Baird
    Qiagen N.V.
    $QGEN
    1/6/2025$48.00Overweight → Equal-Weight
    Morgan Stanley
    Qiagen N.V.
    $QGEN
    12/10/2024$42.50 → $54.00Hold → Buy
    Jefferies
    Pacific Biosciences of California Inc.
    $PACB
    11/11/2024Buy → Neutral
    UBS
    Qiagen N.V.
    $QGEN
    10/17/2024$49.00Buy → Hold
    HSBC Securities
    Qiagen N.V.
    $QGEN
    6/27/2024$50.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $PACB
    $QGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Van Oene Mark sold $35,182 worth of shares (26,836 units at $1.31), decreasing direct ownership by 1% to 1,920,035 units (SEC Form 4)

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    8/20/25 4:06:46 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Mohr Marshall

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    6/6/25 4:10:59 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Livingston Randall S

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    6/6/25 4:10:13 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    $QGEN
    SEC Filings

    View All

    SEC Form 6-K filed by Qiagen N.V.

    6-K - QIAGEN N.V. (0001015820) (Filer)

    8/29/25 6:12:04 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Qiagen N.V.

    6-K - QIAGEN N.V. (0001015820) (Filer)

    8/21/25 5:20:49 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Qiagen N.V.

    SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)

    8/12/25 10:34:25 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PACB
    $QGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Qiagen with a new price target

    Barclays initiated coverage of Qiagen with a rating of Overweight and set a new price target of $55.00

    6/24/25 8:09:28 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Qiagen downgraded by Redburn Atlantic

    Redburn Atlantic downgraded Qiagen from Buy to Neutral

    4/4/25 8:39:19 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Qiagen downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Qiagen from Outperform to Neutral and set a new price target of $42.00 from $52.00 previously

    2/19/25 7:04:54 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PACB
    $QGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Meline David W bought $176,160 worth of shares (40,000 units at $4.40) (SEC Form 4)

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    3/6/24 5:36:07 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    $QGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025

    MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Wednesday, November 5, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the "PacBi

    10/22/25 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities

    MENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today announced innovations to its Revio and Vega platforms designed to lower sequencing costs, add new multiomic capabilities, and expand support for regulated research environments. The advancements center on new SPRQ-Nx sequencing chemistry and consumables, which are designed to deliver PacBio's most affordable HiFi genome to date. Customers operating at scale could see as much as a 40% reduction from current costs, down to a price of less than $300 per genome. Additional improvements include 5hmC detection for epigenetic profiling and 21 CFR Part

    10/14/25 6:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio HiFi Technology Selected as Core Platform for South Korea's National Pangenome Project

    MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that its HiFi sequencing technology has been selected as the primary platform for the Korean Pangenome Reference Project, a landmark national initiative led by the Korea Disease Control and Prevention Agency (KDCA), National Institute of Health (KNIH). The project will generate the first large-scale, telomere-to-telomere quality reference genomes representing the Korean population and integrate the data into the global Human Pangenome Reference Consortium (HPRC). By building a more inclusive and compre

    10/13/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    $QGEN
    Leadership Updates

    Live Leadership Updates

    View All

    PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

    MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access to PacBio's HiFi long-read sequencing technology in clinical and research settings, with a focus on transfusion medicine and hematology, areas where precision and completeness of genomic data are critical to patient outcomes. Founded in 2020, Haorui Gene has quickly become a key player in blood typing genomics, deploying seven Sequel II and three R

    5/22/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jim Gibson to join PacBio as Chief Financial Officer

    MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations. Mr. Gibson joins PacBio from Sequoia, a strategic compensation and benefits solutions provider, where he served as CFO across

    3/27/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service

    MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice President, North America for Sinch AB, a leading global provider of cloud-based communication solutions for business and mobile operators. In his role he led North American sales for the enterprise, mid-market segments. Before that, he held senior sales positions at Zoom V

    2/3/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    $QGEN
    Financials

    Live finance-specific insights

    View All

    PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025

    MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Wednesday, November 5, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the "PacBi

    10/22/25 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast

    QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025. Press release date / time: Tuesday, November 4, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, November 5, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0402 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 3763132 To avoid waiting time, please join the event

    10/13/25 8:24:00 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PacBio Announces Second Quarter 2025 Financial Results

    MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results:  Q2 2025Q2 2024Revenue$39.8 million$36.0 millionInstrument revenue$14.2 million$14.7 millionConsumable revenue$18.9 million$17.0 millionService and other revenue$6.7 million$4.3 millionRevio™ systems1524Vega™ systems38—Annualized Revio pull-through per system~$219,000~$251,000Cash, cash equivalents, and investments$314.7 million$509.8 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspo

    8/7/25 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    $QGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/26/24 8:27:01 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/14/24 5:52:54 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

    SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/14/24 5:48:11 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials